Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GlaxoSmithKline, Novartis deal

Novartis and GlaxoSmithKline announced multi-billion dollar deals that will see the pharmas sell assets to one another. Novartis will bolster its portfolio of marketed cancer drugs and GSK will bulk up its vaccine business. The pharmas also will create a JV focused on OTC drugs.

Read the full 455 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE